Bayisa Lami, Tadesse Abilo, Reta Mebratu Mitiku, Gebeye Ejigu
Department of Internal Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Institute of Public Health, University of Gondar, Gondar, Ethiopia.
HIV AIDS (Auckl). 2020 Sep 24;12:457-465. doi: 10.2147/HIV.S267408. eCollection 2020.
Ethiopia has adopted the "Universal Test and Treat" strategy to its national policy in 2016 to put all people living with HIV/AIDS (PLHIV) on antiretroviral therapy (ART) regardless of their World Health Organization (WHO) clinical stage or CD4 cell count level. A significant percentage of PLHIV start therapy has been delayed despite the availability of ART, which results in poor treatment outcomes including HIV-related morbidity and mortality, and continued HIV transmission.
This cross-sectional study was conducted to determine the magnitude and associated factors of delayed ART initiation among PLHIV at ART Clinic, Nekemte Referral hospital, Western Ethiopia between January 1, 2020 and March 31, 2020 for the time period of January 1, 2016 to December 31, 2019. A consecutive sampling method was used to recruit 417 study subjects. The collected data were entered into Epi data version 3.1 and exported to STATA version 14 for statistical analysis. Logistic regression analysis was used to identify associated factors with delayed ART initiation among PLHIV. -values<0.05 were used to declare significant association.
A total of 417 PLHIV were included in the study. The mean age of study subjects was 33.49 (SD±9.81) years. The majority of participants attended formal education (77%) and were urban dwellers (82%). One-third (34%) of them initiated ART delayed, beyond 7 days of confirmed HIV diagnosis. Subjects with normal nutritional status (BMI=18.5-24.9kg/m) (AOR=3.12, 95% CI=1.29-7.57; =0.012), CD4 count ≥351cells/mm (AOR=2.89, 95% CI=1.27-6.58; =0.011), tuberculosis (TBC) co-infection (AOR=2.76, 95% CI=1.13-6.70; =0.025), use of traditional treatment (AOR=4.03, 95% CI=2.03-8.00; <0.001) and did not know other ART user(s) (AOR=2.86, 95% CI=1.52-5.37; =0.001) were significantly associated with delayed ART initiation.
Early HIV testing mechanisms and timely linkage to HIV care by advocating "Test-and-Treat" should be strengthened.
埃塞俄比亚于2016年在其国家政策中采用了“普遍检测与治疗”策略,以使所有艾滋病毒/艾滋病感染者(PLHIV)无论其世界卫生组织(WHO)临床分期或CD4细胞计数水平如何,都能接受抗逆转录病毒治疗(ART)。尽管有抗逆转录病毒治疗可用,但仍有相当比例的艾滋病毒/艾滋病感染者开始治疗的时间被推迟,这导致治疗效果不佳,包括与艾滋病毒相关的发病率和死亡率,以及艾滋病毒的持续传播。
本横断面研究旨在确定2020年1月1日至2020年3月31日期间,在埃塞俄比亚西部内克梅特转诊医院的抗逆转录病毒治疗诊所中,2016年1月1日至2019年12月31日期间艾滋病毒/艾滋病感染者延迟开始抗逆转录病毒治疗的程度及其相关因素。采用连续抽样方法招募417名研究对象。收集的数据录入Epi data 3.1版本,并导出到STATA 14版本进行统计分析。采用逻辑回归分析确定艾滋病毒/艾滋病感染者延迟开始抗逆转录病毒治疗的相关因素。P值<0.05被视为具有显著相关性。
共有417名艾滋病毒/艾滋病感染者纳入本研究。研究对象的平均年龄为33.49(标准差±9.81)岁。大多数参与者接受过正规教育(77%),并且是城市居民(82%)。其中三分之一(34%)的人在确诊艾滋病毒超过7天后延迟开始抗逆转录病毒治疗。营养状况正常(BMI=18.5-24.9kg/m)的受试者(调整后比值比[AOR]=3.12,95%置信区间[CI]=1.29-7.57;P=0.012)、CD4细胞计数≥351个/mm³(AOR=2.89,95%CI=1.27-6.58;P=0.011)、合并结核病(TBC)感染(AOR=2.76,95%CI=1.13-6.70;P=0.025)、使用传统治疗方法(AOR=4.03,95%CI=2.03-8.00;P<0.001)以及不认识其他接受抗逆转录病毒治疗的人(AOR=2.86,95%CI=1.52-5.37;P=0.001)与延迟开始抗逆转录病毒治疗显著相关。
应加强早期艾滋病毒检测机制,并通过倡导“检测与治疗”及时将患者与艾滋病毒护理联系起来。